My research interests span three major areas: (1) development and evaluation of clinical interventions for adolescents and adults with eating and weight disorders or adults with alcohol use disorders; (2) psychiatric and physical consequences of appearance and performance enhancing drug (APED) use or anabolic androgenic steroid (AAS)use; (3) the biological basis, especially the neuroendocrine and hormonal contributions to eating and substance use disorders.
APEDs and AASs: Currently our lab is conducting the first longitudinal study of APED use among active AAS users and seeks to characterize the desirable and undesirable changes that occur in psychological domains (e.g., body image, aggression, etc.), physical domains (e.g., increases in lean muscle mass), and along the hypothalamic-pituitary-gonadal or hypothalamic-pituitary-adrenal (HPA) axes. This research seeks to identify biomarkers of AAS dependence and ultimately to develop interventions and prevention programs for APED users.
In addition to these focuses, I have a strong interest in advanced quantitative methods including structural equation modeling, latent growth curve modeling, factor mixture modeling, and item response modeling. I teach other professionals and am interested in cognitive behavior therapy for anorexia nervosa, bulimia nervosa, eating disorder not otherwise specified, binge eating disorder across the lifespan.
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
PSYD, Graduate School of Applied and Professional Psychology
Internship, Clinical Psychology
UMDNJ Robert Wood Johnson Medical School
Hildebrandt T, Bacow TL, Markella M, Loeb K. Theoretical mechanisms of action in family therapy for anorexia nervosa: Is there overlap with exposure therapy?. European Eating Disorders Review;.
Hildebrandt T, Yehuda R, Alfano L. What can allostasis tell us about anabolic-androgenic steroid use?. Development and Psychopathology;.
Sysko R, Hildebrandt T. Enhanced cognitive behavior therapy for purging disorder: a case study. European Eating Disorders Review;.
Sysko R, Hildebrandt T, Wilson GT, Wilfley DE, Agras WS. An examination of the diagnostic classification and short-term course of binge eating disorder using latent class and latent transition analyses. Journal of Consulting and Clinical Psychology;.
Hildebrandt T, Epstein E, McCrady B, Cook S. When should clinicians switch treatments: an application of signal detection theory to two different treatments for women with alcohol use disorders. Behavior Research and Therapy;.
Hildebrandt T, Alfano L, Tricamo M, Pfaff D. Conceptualizing the role of estrogens in the development and maintenance of bulimia nervosa. Clinical Psychology Review;.
Hildebrandt T, Alfano L, Langenbucher J. Body image disturbance in 1000 appearance and performance enhancing drugs users. Journal of Psychiatric Research;.
Hildebrandt T, Walker DC, Alfano L, Delsinky SD. Development and validation of the Male Body Checking Questionnaire. International Journal of Eating Disorders 2010; 43(1): 77-87.
Hildebrandt T, Langenbucher J, Carr S, Sanjuan P. Modeling population heterogeneity in appearance and performance enhancing drugs (APED) use: Applications of mixture modeling in 400 regular APED users. Journal of Abnormal Psychology 2007; 116: 717-733.
Hildebrandt T, Langenbucher J, Carr S, Sanjuan P, Roth S, Park S. Predicting short-term versus long-term Intentions for anabolic-androgenic steroid use: A covariance structure model. Psychology of Addictive Behaviors 2006; 20: 234-240.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Hildebrandt during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.